A Randomised, Multi-center, Double Blind (Sponsor Open), Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Severe, Active Rheumatoid Arthritis
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs CHR 5154 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Feb 2018 Status changed from recruiting to discontinued.
- 12 Jan 2018 This trial was discontinued in Poland(on 2017-11-18) according to European Clinical Trials Database record.
- 25 Sep 2017 Planned End Date changed from 4 May 2018 to 1 Feb 2019.